Orexin Receptor Agonist
Alkermes Pushes Narcolepsy Program to Phase III With Highly Competitive Mid-Stage Data
Alkermes; alixorexton; narcolepsy; Phase II trial; Phase III clinical trial; orexin 2 receptor agonist; wakefulness; sleep disorder; clinical endpoints
Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton
Alkermes; narcolepsy; alixorexton; Phase 2 trial; orexin 2 receptor agonist; narcolepsy type 1; normative wakefulness; late-stage testing; Vibrance-1 study; cataplexy; excessive daytime sleepiness